These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24439854)

  • 1. An absence of atherosclerosis progression in a type 2 diabetic patient with multiple atherosclerotic risk factors, complicated with liver cirrhosis.
    Hamasaki H; Yanai H
    Int J Cardiol; 2014; 172(1):e253-4. PubMed ID: 24439854
    [No Abstract]   [Full Text] [Related]  

  • 2. [Diabetes mellitus and cirrhosis of the liver: a prognostically unfavourable combination].
    Wlazlo N; Sauerwein HP; Schoon EJ; Stehouwer CD; Bravenboer B
    Ned Tijdschr Geneeskd; 2011; 155():A2213. PubMed ID: 21329534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels.
    Tan KT; Tayebjee MH; Lim HS; Lip GY
    Diabet Med; 2005 Dec; 22(12):1657-62. PubMed ID: 16401308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Differential diagnosis of diabetes mellitus caused by liver cirrhosis and other type 2 diabetes mellitus].
    Kim MG; Choi WC
    Korean J Hepatol; 2006 Dec; 12(4):524-9. PubMed ID: 17237630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Liver cirrhosis in diabetes mellitus; a complication not always recognized].
    Thewissen CM; Tiebosch AT; Kloppenburg WD; Haagsmna EB; Hoogenberg K
    Ned Tijdschr Geneeskd; 2008 Nov; 152(44):2369-74. PubMed ID: 19055132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microinflammation is a common risk factor for progression of nephropathy and atherosclerosis in Japanese patients with type 2 diabetes.
    Kajitani N; Shikata K; Nakamura A; Nakatou T; Hiramatsu M; Makino H
    Diabetes Res Clin Pract; 2010 May; 88(2):171-6. PubMed ID: 20138680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein (a) as a determinant of arterial stiffness in elderly patients with type 2 diabetes mellitus.
    Wakabayashi I; Masuda H
    Clin Chim Acta; 2006 Nov; 373(1-2):127-31. PubMed ID: 16820145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of patients with cryptogenic liver cirrhosis in Okinawa, Japan.
    Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kobashigawa K; Kinjo F; Saito A
    Hepatogastroenterology; 2003; 50(54):2005-8. PubMed ID: 14696453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [STUDY EFFECT OF ASSOSIATED PATHOLOGY ON THE DEVELOPMENT OF OPTIC NERVE ATROPHY].
    Vasyuta VA
    Lik Sprava; 2015; (7-8):109-12. PubMed ID: 27491161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraoxonase 1: a better atherosclerotic risk predictor than HDL in type 2 diabetes mellitus.
    Patra SK; Singh K; Singh R
    Diabetes Metab Syndr; 2013; 7(2):108-11. PubMed ID: 23680251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryptogenic cirrhosis and NAFLD: are they related?
    Maheshwari A; Thuluvath PJ
    Am J Gastroenterol; 2006 Mar; 101(3):664-8. PubMed ID: 16464222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of site and extent of clinically evident cardiovascular disease and atherosclerotic burden on new cardiovascular events in patients with Type 2 diabetes. The SMART study.
    Gorter PM; Visseren FL; Algra A; van der Graaf Y;
    Diabet Med; 2007 Dec; 24(12):1352-60. PubMed ID: 18042079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies.
    Kadayifci A; Tan V; Ursell PC; Merriman RB; Bass NM
    J Hepatol; 2008 Oct; 49(4):595-9. PubMed ID: 18662837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study.
    Giordanino C; Ceretto S; Bo S; Smedile A; Ciancio A; Bugianesi E; Pellicano R; Fagoonee S; Versino E; Costa G; Arese D; Sacco M; Rizzetto M; Saracco G
    Dig Liver Dis; 2012 May; 44(5):406-12. PubMed ID: 22245505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of liraglutide in a patient with type 2 diabetes and cryptogenic cirrhosis.
    D'Amico E
    Acta Biomed; 2011 Aug; 82(2):160-1. PubMed ID: 22480072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic liver disease in diabetes mellitus.
    Amarapurkar D; Das HS
    Trop Gastroenterol; 2002; 23(1):3-5. PubMed ID: 12170918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential effect of some newer risk factors for atherosclerosis on aortic distensibility in subjects with and without type 2 diabetes.
    Papazafiropoulou A; Tentolouris N; Moyssakis I; Perrea D; Katsilambros N
    Diabetes Care; 2006 Aug; 29(8):1926-8. PubMed ID: 16873806
    [No Abstract]   [Full Text] [Related]  

  • 18. Diabetic retinopathy is associated with subclinical atherosclerosis in newly diagnosed type 2 diabetes mellitus.
    Son JW; Jang EH; Kim MK; Kim IT; Roh YJ; Baek KH; Song KH; Yoon KH; Cha BY; Lee KW; Son HY; Kwon HS
    Diabetes Res Clin Pract; 2011 Feb; 91(2):253-9. PubMed ID: 21129801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyomyositis associated with diabetes mellitus and liver cirrhosis.
    Polizelli DV; Geraldino GC; Narvaes E; Funes E; de Toledo RA; Menin Rde C
    Rev Bras Reumatol; 2010; 50(4):472-7. PubMed ID: 21125181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Incidence of risk factors and vascular complications in patients with newly diagnosed type 2 diabetes mellitus].
    Krahulec B; Vozár J;
    Vnitr Lek; 2002 Nov; 48(11):1031-8. PubMed ID: 12577454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.